Fms-like tyrosine kinase 3 (FLT3)

Overview

FLT3 (FMS-like tyrosine kinase 3), also known as CD135, is a receptor tyrosine kinase encoded by the FLT3 gene and expressed primarily on hematopoietic progenitor cells. It plays an important role in normal blood cell development by transmitting signals that regulate proliferation, survival, and differentiation. In acute myeloid leukemia (AML), FLT3 is one of the most clinically important signaling proteins because activating alterations can drive malignant growth and are associated with aggressive disease biology.

Pathogenic FLT3 alterations include internal tandem duplication (FLT3-ITD) and other activating mutations that lead to constitutive kinase signaling. These aberrations can promote downstream pathways such as STAT5A, mitogen-activated protein kinase 1 (MAPK1), and Akt1, contributing to leukemic cell survival and expansion. Because of this central role in AML pathogenesis, FLT3 has become a major therapeutic target, and multiple FLT3 inhibitors are used or investigated in mutation-defined AML subsets.

Recent Publications Summary

Recent publications on FLT3 have focused heavily on acute myeloid leukemia, especially FLT3-ITD–positive disease, and on strategies to inhibit FLT3 directly or exploit FLT3-associated biology. Several studies reported the discovery or optimization of small-molecule FLT3 inhibitors with improved potency, selectivity, or drug-like properties. Nintedanib was identified as a putative FLT3 inhibitor with direct target engagement confirmed by docking, CETSA, and kinase assays; in FLT3-ITD-mutant cell lines, primary AML blasts, and engineered Ba/F3 models, it suppressed FLT3 autophosphorylation and downstream signaling 42035942Apr. A separate medicinal chemistry study described staurosporine-type indolocarbazole glycoalkaloids, with compound 35 showing potent inhibition of FLT3-ITD and FLT3-WT and strong selectivity for FLT3-ITD-mutant cells 41889033Mar. Another computational design study optimized a known FLT3 inhibitor scaffold to generate an analogue with improved predicted pharmacokinetic properties, stronger docking interactions, and greater conformational stability in molecular dynamics simulations 42144504May.

Other reports examined FLT3-targeted therapy in combination settings or in clinical use. In preclinical AML models, the p300/CBP bromodomain inhibitor inobrodib combined with venetoclax and gilteritinib nearly eliminated leukemia stem cells in DNMT3A/FLT3-mutant AML, suggesting potential utility for triplet therapy 42139346May. A real-world study evaluated gilteritinib maintenance after allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations, addressing a setting in which evidence has been limited 42230462Jun. Post-marketing surveillance of quizartinib in Japan provided safety data in relapsed/refractory FLT3-ITD-positive AML, including rates of adverse drug reactions and QT prolongation 41746494Feb. In addition, a clinical study found that high CD135/FLT3 receptor expression in de novo AML was associated with lower induction response rates and poorer overall and progression-free survival, with subgroup analyses suggesting relevance in patients with FLT3-ITD mutations 42067641May.

Mechanistic and structural studies further expanded understanding of FLT3 biology and inhibitor behavior. One report mapped the ATP-binding pockets of FLT3 and TAK1, showing that several approved FLT3 inhibitors also bind TAK1 because of structural similarity between the active sites, despite limited sequence homology 42151107May. Another study integrated transcriptomic and survival analyses to identify SYK and HDAC isoforms as age- and FLT3-dependent prognostic markers in AML, then developed a dual SYK-HDAC inhibitor that was active in MV4-11 cells and in a FLT3-ITD-positive AML xenograft model, where it reduced tumor mass by about 80% 42262889Jun. Together, these publications highlight ongoing efforts to target FLT3 directly, overcome resistance, refine combination regimens, and use FLT3-related biomarkers to guide prognosis and therapy 42035942Apr42139346May42067641May41746494Feb42262889Jun.

What Changes, What Holds

1. Direct FLT3 inhibition is being expanded from canonical AML drugs to new chemotypes and design strategies
REINFORCES These studies do not alter the baseline view that FLT3 is a major therapeutic target in mutation-defined AML; they strengthen it by showing that additional scaffolds can engage the kinase and suppress FLT3-driven signaling. The practical implication is that the inhibitor space is still broadening, but the underlying model of FLT3 as a druggable driver in FLT3-ITD disease remains intact 42035942Apr41889033Mar.

2. FLT3-targeted therapy is moving toward combination, maintenance, and biomarker-guided use
NEW DIRECTION The new work extends FLT3 beyond single-agent inhibition by suggesting where it may fit in triplets, post-transplant maintenance, and risk stratification. That does not contradict the baseline role of FLT3 in AML, but it does add a more operational understanding: FLT3 expression and mutation status may help define who benefits most, while combination regimens may be needed to deepen responses and address leukemia stem cells 42139346May42230462Jun.

3. Structural similarity can make some FLT3 inhibitors less selective than assumed
NEW DIRECTION Mapping of ATP-binding pockets shows that the Overview’s therapeutic target is not pharmacologically isolated: several approved FLT3 inhibitors also hit TAK1 because the active sites resemble each other. That broadens how FLT3 drugs should be interpreted, especially for off-target effects and resistance biology, but it does not displace the established role of FLT3 in AML. The finding is mechanistic and should be settled with broader biochemical and in vivo selectivity work 42151107May.

Overview update candidates: FLT3-targeted therapy may be used in combination/maintenance settings and FLT3 expression may have prognostic value; some FLT3 inhibitors also inhibit TAK1 because of active-site similarity.